-
公开(公告)号:US20130261105A1
公开(公告)日:2013-10-03
申请号:US13851189
申请日:2013-03-27
申请人: Dirk GOTTSCHLING , Heiner EBEL , Doris RIETHER , Bernd WELLENZOHN
发明人: Dirk GOTTSCHLING , Heiner EBEL , Doris RIETHER , Bernd WELLENZOHN
IPC分类号: C07D513/04 , C07D495/04 , C07D487/04
CPC分类号: C07D513/04 , C07D471/04 , C07D487/04 , C07D495/04
摘要: This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
摘要翻译: 本发明涉及新的吡唑并嘧啶及其作为代谢型谷氨酸受体5受体拮抗剂(mGlu5受体拮抗剂),含有它们的药物组合物的用途及其用于治疗或改善mGlu5受体介导的病症的药物的方法。
-
公开(公告)号:US20130150341A1
公开(公告)日:2013-06-13
申请号:US13692019
申请日:2012-12-03
申请人: Matthias GRAUERT , Daniel BISCHOFF , Georg DAHMANN , Raimund KUELZER , Klaus RUDOLF , Bernd WELLENZOHN
发明人: Matthias GRAUERT , Daniel BISCHOFF , Georg DAHMANN , Raimund KUELZER , Klaus RUDOLF , Bernd WELLENZOHN
IPC分类号: C07D513/04 , C07D401/06 , C07D413/14 , C07D471/04 , C07D487/04 , C07D403/14 , C07D409/14 , C07D417/14 , C07D401/14
CPC分类号: C07D513/04 , C07D249/08 , C07D401/06 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
摘要翻译: 本发明涉及式I化合物,其用作mGlu5受体活性的正变构调节剂,含有它们的药物组合物,以及将其用作用于治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的药剂的方法,例如 精神分裂症或认知衰退如痴呆或认知障碍。 A,B,X,R 1,R 2,R 3具有说明书中给出的含义。
-
公开(公告)号:US20130158011A1
公开(公告)日:2013-06-20
申请号:US13709330
申请日:2012-12-10
申请人: Klaus RUDOLF , Daniel BISCHOFF , Georg DAHMANN , Matthias GRAUERT , Raimund KUELZER , Bernd WELLENZOHN
发明人: Klaus RUDOLF , Daniel BISCHOFF , Georg DAHMANN , Matthias GRAUERT , Raimund KUELZER , Bernd WELLENZOHN
IPC分类号: C07D513/04 , C07D413/14 , C07D403/06 , C07D498/04
CPC分类号: C07D513/04 , C07D233/64 , C07D403/06 , C07D413/12 , C07D413/14 , C07D498/04
摘要: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
-
公开(公告)号:US20130158042A1
公开(公告)日:2013-06-20
申请号:US13709312
申请日:2012-12-10
IPC分类号: C07D513/04 , C07D401/14 , C07D487/04 , C07D417/14 , C07D471/04 , C07D405/14 , C07D403/14
CPC分类号: C07D513/04 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.
摘要翻译: 本发明涉及式I化合物,其用作mGlu5受体活性的正变构调节剂,含有它们的药物组合物,以及将其用作用于治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的药剂的方法,例如 精神分裂症或认知衰退如痴呆或认知障碍。 R1,R2,R3,R4,Q具有说明书中给出的含义。
-
公开(公告)号:US20130150347A1
公开(公告)日:2013-06-13
申请号:US13707718
申请日:2012-12-07
申请人: Klaus RUDOLF , Daniel BISCHOFF , Georg DAHMANN , Matthias GRAUERT , Raimund KUELZER , Bernd WELLENZOHN
发明人: Klaus RUDOLF , Daniel BISCHOFF , Georg DAHMANN , Matthias GRAUERT , Raimund KUELZER , Bernd WELLENZOHN
IPC分类号: C07D513/04 , C07D403/06 , C07D401/14 , C07D498/04
CPC分类号: C07D513/04 , C07D401/14 , C07D403/06 , C07D498/04
摘要: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
-
公开(公告)号:US20130143870A1
公开(公告)日:2013-06-06
申请号:US13689867
申请日:2012-11-30
申请人: Matthias GRAUERT , Daniel BISCHOFF , Georg DAHMANN , Raimund KUELZER , Klaus RUDOLF , Bernd WELLENZOHN
发明人: Matthias GRAUERT , Daniel BISCHOFF , Georg DAHMANN , Raimund KUELZER , Klaus RUDOLF , Bernd WELLENZOHN
IPC分类号: C07D231/12 , C07D487/04 , C07D413/14 , C07D513/04 , C07D401/04 , C07D401/14
CPC分类号: C07D231/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04 , C07D498/04 , C07D513/04
摘要: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
-
公开(公告)号:US20130065906A1
公开(公告)日:2013-03-14
申请号:US13418376
申请日:2012-03-13
申请人: Bernd NOSSE , Andreas BLUM , Steffen BREITFELDER , Armin HECKEL , Frank HIMMELSBACH , Elke LANGKOPF , Bernd WELLENZOHN , Neil J. ASHWEEK , Nicole HARRIOTT
发明人: Bernd NOSSE , Andreas BLUM , Steffen BREITFELDER , Armin HECKEL , Frank HIMMELSBACH , Elke LANGKOPF , Bernd WELLENZOHN , Neil J. ASHWEEK , Nicole HARRIOTT
IPC分类号: C07D413/14 , A61K31/4545 , C07D417/14 , A61K31/506 , A61P3/06 , A61K31/497 , A61K31/501 , C07D401/14 , A61P3/10 , A61P3/04 , A61K31/454 , C07D413/04
CPC分类号: C07D413/14 , C07D413/04 , C07D417/14
摘要: The present invention relates to compounds of general formula I, wherein the groups R1, LP, LQ, Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
摘要翻译: 本发明涉及通式I的化合物,其中R1,LP,LQ,Ar,m和n基团如本申请中所定义,其具有有价值的药理学性质,特别是与GPR119受体结合并调节其活性 。
-
-
-
-
-
-